|
Jun 12
|
New results for Johnson & Johnson's bleximenib demonstrate promising antileukemic activity in combination with venetoclax and azacitidine for acute myeloid leukemia
|
|
Jun 12
|
J&J’s Tremfya reduces active psoriatic arthritis symptoms in Phase IIIb trial
|
|
Jun 11
|
Judge Orders J&J Subsidiary to Pay $442 Million in Antitrust Lawsuit
|
|
Jun 11
|
Daniel Pinto Joins Johnson & Johnson (NYSE:JNJ) Board Bringing Extensive Financial Expertise
|
|
Jun 11
|
Trump Trade: RFK Jr. removes members of vaccine-advising CDC panel
|
|
Jun 11
|
Why Johnson & Johnson (JNJ) is a Top Momentum Stock for the Long-Term
|
|
Jun 11
|
JNJ vs. MRK: Which Healthcare Titan Offers Better Growth Prospects?
|
|
Jun 11
|
The Zacks Analyst Blog Highlights Johnson & Johnson, T-Mobile, The Boeing and Franklin Financial Services
|
|
Jun 11
|
New data show TREMFYA® (guselkumab) is the only IL-23 inhibitor proven to significantly inhibit progression of joint structural damage in active psoriatic arthritis
|
|
Jun 11
|
Why defensive stocks could be your best bet in a wild market
|
|
Jun 11
|
Johnson & Johnson MedTech introduces surgical stapler for tissue complexity
|
|
Jun 10
|
Johnson & Johnson Elects Daniel Pinto, President, JPMorganChase to its Board of Directors
|
|
Jun 10
|
Top Analyst Reports for Johnson & Johnson, T-Mobile US & Boeing
|
|
Jun 10
|
RFK Jr. removes CDC vaccine panel members: What to know
|
|
Jun 10
|
Have Skyrizi and Rinvoq Successfully Saved AbbVie From Humira LoE?
|
|
Jun 9
|
Judge rules J&J unit must pay $442M in antitrust case
|
|
Jun 7
|
Corporate cash levels are starting to fall
|
|
Jun 7
|
Patents and economies of scale support Pfizer's wide moat
|
|
Jun 6
|
Challenges pharma companies face in push into US manufacturing
|
|
May 1
|
'Declare victory and move on': Eli Lilly CEO on Trump tariff threat
|